Background
Methods
Study identification and selection
Data extraction
Study | Country | Follow-up period | Baseline population | Exposurea
| Referenceb
| Cancers studied (cases)c
|
---|---|---|---|---|---|---|
Lutheran Brotherhood cohortd
| USA | 1966 to 1986 | 17,633 white men aged 35+ years | ST | Hsing et al. 1990 [11] | Prostate (149) |
Kneller et al. 1991 [12] | Stomach (75) | |||||
Zheng et al. 1993 [13] | Pancreas (57) | |||||
US Veterans cohorte
| USA | 1954/57 to 1980 | 248,046 US veterans aged 31–84 years, over 99.5% men | ST | Hsing et al. 1991 [15] | Prostate (4,607) |
Heineman et al. 1992 [16] | Multiple myeloma (582)f
| |||||
Zahm et al. 1992 [17] | Soft tissue sarcoma (119), pharynx (55), buccal cavity (74) | |||||
Heineman et al. 1995 [18] | Colon (3,812), rectum (1,100) | |||||
Iowa cohort | USA | 1986/89 to 1995 | 1,572 men aged 40+ years, controls in a case-control study | ST | Putnam et al. 2000 [20] | Prostate (101)f
|
NHANES I follow-up cohortg
| USA | 1971/75 to 2002 | 14,407 adults aged 25–74 yearsh
| ST | Accort et al. 2002 [21] | All, lungi
|
Accort et al. 2005 [22] | All, lung, breast, digestive, oral, prostatef, i
| |||||
CPS-Ij
| USA | 1959 to 1972 | 77,407 never smoking men aged 30+ years from 25 states | ST | Henley et al. 2005 [23] | All (2,332), oral (13), digestive (913), lung (134), genitourinary (559) |
CPS-IIk
| USA | 1982 to 2000 | 114,809 never smoking men aged 30+ years nationwide | STl
| Henley et al. 2005 [23] | All (6,140), oral (46), digestive (1,999), lung (400), genitourinary (1,709), haematopoietic (923) |
1982 to 1996 | 467,788 men aged 30+ years nationwide | ST | Chao et al. 2002 [24] | Stomach (996) | ||
Norway cohortsm
| Norway | 1966 to 2001 | 10,136 men from two cohorts, a sample of the 1960 census and relatives of Norwegian migrants to the USA | Snuff | Boffetta et al. 2005 [26] | Oral (34), oesophagus (27), stomach (217), pancreas (105), lung (343), kidney (88), bladder (239)n
|
Swedish construction workers | Sweden | 1974 to 1985 | 135,036 men | Snuff | Bolinder et al. 1994 [28] | All (1,269), lung (204) |
1971 to 2000 | 337,311 men | Odenbro et al. 2005 [29] | Cutaneous squamous cell carcinoma (756)f
| |||
1971 to 2000 | 335,612 adults, over 99.3% men | Fernberg et al. 2006 [30] | Malignant lymphoma (1,514)f
| |||
1971 to 2004 | 336,381 men | Fernberg et al. 2007 [31] | Leukaemia (372), multiple myeloma (520)f
| |||
1978 to 2004 | 279,897 men | Luo et al. 2007 [32] | Oral (248), lung (2,198), pancreas (448)f
| |||
1971 to 2004 | 339,802 men | Odenbro et al. 2007 [33] | Melanoma (1,639)° | |||
1971 to 2004 | 336,381 men | Zendehdel et al. 2008 [34] | Stomach (1,385), oesophagus (366)f
| |||
Uppsala County cohort | Sweden | 1973/74 to 2002 | 9,976 men | Snuff | Roosaar et al. 2008 [35] | All (1,572), smoking-related (493), oral (34)p
|
Study | Country | Study perioda
| Controlsa
| Sexb
| Exposures studiedc
| Cancers studied (cases)d
|
---|---|---|---|---|---|---|
Broders 1920 [37] | USA | NA | Hospital | M+F | Chew, snuff, ST | Oral (537) |
Doll and Hill 1952 [38] | UK | 1948–1952 | Hospital | M | Chew, snuff | Lung (1,209) |
Moore et al. 1953 [39] | USA | 1951–1952 | Hospital | M | ST | Oral (112), face (93) |
Wynder et al. 1957 [40] | Sweden | 1952–1955 | Hospital | M | Chew | Oral (166), oesophagus (39), larynx (60) |
Wynder and Bross 1957 [41] | USA | NA | Hospital | M | Chew | Oral (543) |
Peacock et al. 1960 [42] | USA | 1952–1958 | Hospital | M+F | ST | Oral (45) |
Lockwood 1961 [43] | Denmark | 1942–1956 | Population | M+F | ST | Bladder (282) |
Wynder and Bross 1961 [44] | USA | 1956–1959 | Hospital | M | Chew | Oesophagus (150) |
Vogler et al. 1962 [36] | USA | 1956–1957 | Hospital | M+F | Chew, snuff | Oral (228) |
Vincent and Marchetta 1963 [45] | USA | NA | Hospital | M | Snuff | Oral (66), larynx (23) |
Wynder et al. 1963 [46] | USA | 1957–1960 | Hospital | M | Chew, snuff, ST | Bladder (300) |
Bennington and Laubscher 1968 [47] | USA | 1951–1956 | Hospital | M | Chew | Kidney (88) |
Dunham et al. 1968 [48] | USA | 1958–1964 | Hospital | M+F | ST | Bladder (493) |
Martinez 1969 [49] | Puerto Rico | 1966 | Hospital, population | M+F | Chew | Oral (221), oesophagus (179) |
Keller 1970 [50] | USA | 1958–1962 | Hospital | M | ST | Oral (314) |
Cole et al. 1971 [51] | USA | 1967–1968 | Population | M+F | Chew, snuff | Bladder (470) |
Bjelke et al. 1974 [52] | USA | NA | NA | NA | Chew | Colorectal (373), oesophagus (52), stomach (83) |
Norway | NA | NA | NA | Chew | Colorectal (278), stomach (228) | |
Armstrong et al. 1976 [53] | UK | 1972–1974 | Hospital | M | ST | Kidney (96) |
Browne et al. 1977 [54] | UK | 1957–1971 | Population | M+F | Chew | Oral (75) |
Williams and Horm 1977 [55] | USA | 1969–1971 | Hospital | M+F | ST | Many types (7,518)e
|
Wynder and Stellman 1977 [56] | USA | 1969–1975 | Hospital | M | Chew, snuff, ST | Oral (593), bladder (589), larynx (387), lung (1,051), oesophagus (183) |
Engzell et al. 1978 [57] | Sweden | 1961–1971 | Population | M | Snuff | Nose (36) |
Howe et al. 1980 [58] | Canada | 1974–1976 | Population | M | Chew | Bladder (480) |
Westbrook et al. 1980 [59] | USA | 1955–1975 | Hospital | F | Snuff | Oral (55) |
Pottern et al. 1981 [60] | USA | 1975–1977 | Decedent | M | Chew, snuff | Oesophagus (120) |
Winn et al. 1981 [61] | USA | 1975–1978 | Hospital | F | Snuff | Oral (255) |
Mommsen and Aagaard 1983 [62] | Denmark | 1977–1980 | Population | M | Chew | Bladder (165) |
Wynder et al. 1983 [63] | USA | 1977–1980 | Hospital | M | Chew, snuff, ST | Oral (414) |
Brinton et al. 1984 [64] | USA | 1970–1980 | Hospital, decedent | M+F | Chew, snuff, ST | Nose (160) |
McLaughlin et al. 1984 [65] | USA | 1974–1979 | Population | M | Chew, snuff, ST | Kidney (313) |
Hartge et al. 1985 [66] | USA | 1977–1978 | Population | M | Chew, snuff, ST | Bladder (2,240) |
Weinberg et al. 1985 [67] | USA | 1978–1980 | Decedent, population | M | Chew | Stomach (178) |
Goodman et al. 1986 [68] | USA | 1977–1983 | Hospital | M+F | Chew | Kidney (267) |
Kabat et al. 1986 [69] | USA | 1976–1983 | Hospital | F | Snuff | Bladder (152) |
Stockwell and Lyman 1986 [70] | USA | 1982 | Population | M+F | ST | Oral (1,462), nose (92), larynx (161) |
Young et al. 1986 [71] | USA | 4 yr period | Hospital | M+F | ST | Oral (317), larynx (179) |
Lindquist et al. 1987 [72] | Sweden | 1980–1983 | Population | M | Snuff | Leukaemia (76) |
Asal et al. 1988 [73] | USA | 1981–1984 | Hospital, population | M | Snuff | Kidney (209) |
Blot et al. 1988 [74] | USA | 1984–1985 | Population | M+F | ST | Oral (1,114) |
Falk et al. 1988 [75] | USA | 1979–1983 | Hospital | M+F | Chew, snuff | Pancreas (363) |
Morris Brown et al. 1988 [76] | USA | 1982–1984 | Population | M | ST | Oesophagus (207) |
Slattery et al. 1988 [77] | USA | 1977–1983 | Population | M | Chew, snuff, ST | Bladder (332) |
Spitz et al. 1988 [78] | USA | 1985–1987 | Hospital | M+F | Chew, snuff, ST | Oral (185)f
|
Burch et al. 1989 [79] | Canada | 1979–1982 | Population | M | Chew, snuff | Bladder (627) |
Franco et al. 1989 [80] | Brazil | 1986–1988 | Hospital | M+F | ST | Oral (232) |
Zahm et al. 1989 [81] | USA | 1976–1982 | Population | M | ST | Soft tissue sarcoma (133) |
Farrow et al. 1990 [82] | USA | 1982–1986 | Population | M | Chew | Pancreas (148) |
Blomqvist et al. 1991 [83] | Sweden | NA | Hospital | M+F | Snuff | Oral (61) |
Ghadirian et al. 1991 [84] | Canada | 1984–1988 | Population | M+F | Chew | Pancreas (179) |
Maden et al. 1992 [85] | USA | 1985–1989 | Population | M | ST | Oral (131) |
Marshall et al. 1992 [86] | USA | 1975–1983 | Population | M+F | Chew | Oral (290) |
Morris Brown et al. 1992 [87] | USA | 1981–984 | Population | M | ST | Leukaemia (578) |
Morris Brown et al. 1992 [88] | USA | 1981–1984 | Population | M | ST | Non-Hodgkin's lymphoma (622) |
Sterling et al. 1992 [89] | USA | 1986 | Population | M+F | Snuff, ST | All cancer (459,792), oral (6,976), all digestive (109,514) |
Mashberg et al. 1993 [90] | USA | 1972–1989 | Hospital | M | Chew, snuff, ST | Oral (359) |
Perry et al. 1993g
| USA | About 1992 | Hospital | M+F | ST | Oral (133) |
Spitz et al. 1993 [92] | USA | 1987–1991 | Hospital | M+F | Chew | Oral (108)f
|
Chow et al. 1994 [93] | USA | 1985–1997 | Population | M | Chew | Bile duct (49) |
Hansson et al. 1994 [94] | Sweden | 1989–1992 | Population | M+F | Chew, snuff | Stomach (338) |
Hardell et al. 1994 [95] | Sweden | 1974–1978 | Population | M | Snuff | Non-Hodgkin's lymphoma (105) |
Hayes et al. 1994 [96] | USA | 1986–1989 | Population | M | Chew, snuff, ST | Prostate (981) |
Kabat et al. 1994 [97] | USA | 1977–1990 | Hospital | M+F | Chew, snuff | Oral (1,560) |
Bundgaard et al. 1995 [98] | Denmark | 1986–1990 | Population | M+F | Chew | Oral (161) |
McLaughlin et al. 1995 [99] | 5 countriesh
| 1989–1991 | Population | M+F | ST | Kidney (1,732) |
Muscat et al. 1995 [100] | USA | 1977–1993 | Hospital | M | Chew | Kidney (543) |
Muscat et al. 1997 [101] | USA | 1985–1993 | Hospital | M | Chew, snuff | Pancreas (290) |
Lewin et al. 1998 [102] | Sweden | 1980–1989 | Population | M | Snuff | Oral (266), larynx (157), oesophagus (122) |
Muscat and Wynder 1998 [103] | USA | 1977–1980 | Hospital | M+F | Chew, ST | Oral (128) |
Schildt et al. 1998 [104] | Sweden | 1980–1989 | Population | M+F | Chew, snuff, ST | Oral (410) |
Schwartz et al. 1998 [105] | USA | 1990–1995 | Population | M | ST | Oral (165) |
Yuan et al. 1998 [106] | USA | 1986–1994 | Population | M+F | ST | Kidney (1,204) |
Ye et al. 1999 [107] | Sweden | 1989–1995 | Population | M+F | Chew, snuff | Stomach (514) |
Lagergren et al. 2000 [108] | Sweden | 1995–1997 | Population | M+F | Snuff | Oesophagus (189), stomach (429) |
Zheng et al. 2001 [109] | USA | NA | Population | M+F | Chew, snuff | Brain (375) |
Schroeder et al. 2002 [110] | USA | 1980–1982 | Population | M | Chew, snuff, ST | Non-Hodgkin's lymphoma (182) |
Alguacil and Silverman 2004 [111] | USA | 1986–1989 | Population | M+F | ST | Pancreas (526) |
Bracci and Holly 2005 [112] | USA | 1988–1993 | Population | M | ST | Non-Hodgkin's lymphoma (725) |
Rosenquist et al. 2005 [113] | Sweden | 2000–2004 | Population | M+F | Snuff | Oral (132) |
Hassan et al. 2007 [114] | USA | 2000–2006 | Hospital | M+F | Chew, snuff, ST | Pancreas (808) |
Data presentation
Source
ST use – type
ST use – exposure
Smoking
Sex
RR/OR id
Cases
Estimate (95% CI)
Adjustment factors
Layout
Meta-analysis
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sex | Id. | Casesd
| Estimate (95%CI) | Adjustment factorse
|
Cohort studies
| ||||||||
US Veterans: Zahm et al. 1992 [17] | ST | Ever | Any | Mf
| 1 | 129 | 4.11 (2.90–5.84)g
| age, time |
CPS-I: Henley et al. 2005 [23] | ST | Current | Never | M | 2 | 4 | 2.02 (0.53–7.74) | age, alc, asp, bmi, diet, edu, exer, occ, race |
CPS-II: Henley et al. 2005 [23] | ST | Current | Never | M | 3 | 1 | 0.90 (0.12–6.71) | age, alc, asp, bmi, diet, edu, exer, occ, race |
Norway Cohorts: Boffetta et al. 2005 [26] | Snuff | Current | Any | M | 4 | 6 | 1.13 (0.45–2.83) | age, smok |
Former | 5 | 3 | 1.04 (0.31–3.50) | |||||
Ever | 6 | 9 | 1.10 (0.50–2.41) | |||||
Swedish construction workers: Luo et al. 2007 [32] | Snuff | Ever | Any | M | 7 | NA | 0.70 (0.50–0.90) | age, bmi, smok |
Current | Never | 8 | 9 | 0.90 (0.40–1.80) | age, bmi | |||
Former | 9 | 1 | 0.70 (0.10–5.00) | |||||
Ever | 10 | 10 | 0.80 (0.40–1.70) | |||||
Uppsala County: Roosaar et al. 2008 [35] | Snuff | Ever | Any | M | 11 | 11 | 3.10 (1.50–6.60) | age, alc, res, smok, time |
Never | 12 | 5 | 2.30 (0.70–8.30) | age, alc, res, time | ||||
Case-control studies
| ||||||||
Broders 1920 [37] | Chew | Use | Any | M+F | 13 | 128 | 2.05 (1.48–2.83)g
| smok |
Snuff | 14 | 2 | 1.76 (0.12–26.52)g
| none | ||||
ST | 15 | 130 | 2.05 (1.48–2.83)g
| |||||
Moore et al. 1953 [39] | ST | Use | Any | M | 16 | 65 | 3.00 (1.37–6.54)g
| none |
Wynder et al. 1957 [40] | Chew | Ever | Any | M | 17 | NA | no associationh
| none |
Wynder and Bross 1957 [41] | Chew | Ever | Any | M | 18 | 91 | 2.00 (1.16–3.47)g
| smok |
Peacock et al. 1960 [42] | ST | Use | Any | M | 19 | 14 | 3.06 (1.08–8.63)g
| age, ins |
F | 20 | 11 | 2.00 (0.66–6.01)g
| |||||
Vogler et al. 1962 [36] | Chew | Ever | Any | M | 21 | 46 | 7.38 (4.31–12.62)g
| none |
Snuff | F | 22 | 54 | 38.28 (21.49–68.15)g
| ||||
Vincent and Marchetta 1963 [45] | Snuff | Use | Any | M | 23 | 12 | 4.22 (1.41–12.63)g
| none |
Martinez et al. 1969 [49] | Chew | Use | Any | M | 24 | 4 | 2.29 (0.62–8.48)g
| none |
F | 25 | 1 | 0.34 (0.04–2.79)g
| |||||
Keller 1970 [50] | ST | Use | Any | M | 26 | 11 | 3.63 (1.02–12.95)g
| smok |
Never | 27 | 4 | 3.04 (0.62–14.99)g
| |||||
Browne et al. 1977 [54] | Chew | Use | Any | M+F | 28 | 7 | 0.67 (0.27–1.66)g
| none |
Williams and Horm 1977 [55] | ST | Ever | Any | M | 29 | 16 | 0.91 (0.53–1.56)g
| none |
F | 30 | 2 | 1.54 (0.37–6.42)g
| |||||
Wynder and Stellman 1977 [56] | Chew | Ever | Any | M | 31 | 10 | 0.62 (0.32–1.21)g
| none |
Snuff | 32 | 61 | 1.15 (0.85–1.55)g
| |||||
ST | 33 | 71 | 1.02 (0.78–1.34)i
| |||||
Westbrook et al. 1980 [59] | Snuff | Ever | Any | F | 34 | 50 | 540.00 (60.97–4782.82)g
| none |
Winn et al. 1981 [61] | Snuff | Ever | Any | F | 35 | 107 | 2.67 (1.83–3.90)g
| race, smok |
Wynder et al. 1983 [63] | Chew | Ever | Any | M | 36 | 37 | 1.00 (0.62–1.61)g
| none |
Snuff | 37 | 12 | 0.42 (0.11–1.65)g
| |||||
ST | 38 | 49 | 0.90 (0.57–1.41)i
| |||||
Stockwell and Lyman 1986 [70] | ST | Ever | Any | M+F | 39 | 11 | 2.02 (1.01–4.02)g
| none |
Young et al. 1986 [71] | ST | Ever | Any | M | 40 | NA | no association | none |
Blot et al. 1988 [74] | ST | Ever | Any | M | 41 | 46 | 0.85 (0.57–1.26)g
| none |
F | 42 | 11 | 3.44 (1.09–10.91)g
| |||||
Never | F | 43 | 6 | 6.20 (1.90–19.80) | age, race, res, resp | |||
Spitz et al. 1988 [78] | Chew | Ever | Any | M+F | 44 | 23 | 1.00 (0.54–1.85)g
| none |
Snuff | 45 | 9 | 3.40 (1.00–10.90) | |||||
ST | 46 | 25 | 1.05 (0.57–1.91)g
| |||||
Franco et al. 1989 [80] | ST | Use | Any | M+F | 47 | 9 | 1.40 (0.59–3.33)g
| none |
Blomqvist et al. 1991 [83] | Snuff | Ever | Never | M+F | 48 | 2 | 0.67 (0.08–5.75)g
| none |
Maden et al. 1992 [85] | ST | Ever | Any | M | 49 | 19 | 4.50 (1.50–14.30) | age |
Marshall et al. 1992 [86] | Chew | Use | Any | M | 50 | NA | no significant association | none |
Sterling et al. 1992 [89] | ST | Ever | Any | M+F | 51 | 28g
| 1.04 (0.41–2.68)g
| age, alc, occ, race, sex, smok |
Snuff | Ever | Any | M+F | 52 | NA | 2.42 (1.28–4.59) | age, race, sex | |
Mashberg et al. 1993 [90] | Chew | Ever | Any | Mf
| 53 | NA | 1.00 (0.70–1.40) | age, alc, race, smok |
Snuff | 54 | NA | 0.80 (0.40–1.90) | |||||
ST | 55 | 52 | 0.96 (0.70–1.33)i
| |||||
Perry et al. 1993j
| ST | Use | Any | M+F | 56 | 10 | 1.43 (0.64–3.21)g
| age, alc, occ, race, sex, smok |
Spitz et al. 1993 [92] | Chew | Use | Any | M+F | 57 | NA | 1.20 (not significant) | none |
Kabat et al. 1994 [97] | Chew | Ever | Any | M | 58 | 67 | 1.11 (0.81–1.53)g
| smok |
Snuff | Ever | Never | M+F | 59 | 4 | 4.79 (1.19–19.30)g
| none | |
Bundgaard et al. 1995 [98] | Chew | Ever | Any | M+F | 60 | 8 | 1.44 (0.59–3.51)g
| none |
Lewin et al. 1998 [102] | Snuff | Current | Any | M | 61 | 18 | 0.84 (0.47–1.50)g
| age, alc, res, smok |
Former | 62 | 22 | 1.28 (0.70–2.35)g
| |||||
Ever | 63 | 40 | 0.98 (0.63–1.50)g
| |||||
Muscat et al. 1998 [103] | Chew | Ever | Any | M+F | 64 | 3 | 0.89 (0.18–4.49)g
| none |
ST | 65 | 4 | 1.19 (0.26–5.45)i
| |||||
Schildt et al. 1998 [104] | Chew | Use | Any | M+F | 66 | 5 | 0.60 (0.20–2.00) | age, sex, res |
Snuff | Current | 67 | 39 | 0.70 (0.40–1.10) | ||||
Former | 68 | 28 | 1.50 (0.80–2.90) | |||||
Ever | 69 | 67 | 0.80 (0.50–1.30) | age, alc, sex, smok, res | ||||
Current | Never | 70 | 19 | 0.70 (0.40–1.20) | age, sex, res | |||
Former | 71 | 9 | 1.80 (0.90–3.50) | |||||
Ever | 72 | 28 | 1.01 (0.64–1.57)g
| |||||
ST | Ever | Any | 73 | 72 | 0.87 (0.61–1.25)i
| none | ||
Schwartz et al. 1998 [105] | ST | Ever | Any | M | 74 | NA | 1.00 (0.40–2.30) | age, alc, smok |
Rosenquist et al. 2005 [113] | Snuff | Current | Any | M+F | 75 | 13 | 1.10 (0.50–2.50) | alc, smok |
Former | 76 | 7 | 0.30 (0.10–0.90) | |||||
Ever | 77 | 20 | 0.70 (0.30–1.30) |
Sensitivity analysis
Meta-regression analysis
Estimating deaths attributable to smoking
Estimating deaths attributable to ST in a population of never smokers
Results
Cohort studies
Case-control studies
Adjustment for smoking
Oropharyngeal cancer
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any | Overall data |
n = 41 (1, 2, 3, 6, 7, 11, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 33, 34, 35, 38, 39, 41, 42, 46, 47, 48, 49, 51, 55, 56, 58, 60, 63, 65, 73, 74, 77) | 1.79 (1.36–2.36) | 335.6 | 88.1 | < 0.001 |
Smoking-adjusted |
n = 19 (2, 3, 6, 7, 11, 13, 18, 26, 35, 43, 48, 51, 55, 56, 58, 63, 69, 74, 77) | 1.36 (1.04–1.77) | 69.5 | 74.1 | < 0.001 | |
Smoking and alcohol adjusted |
n = 10 (2, 3, 11, 51, 55, 56, 63, 69, 74, 77) | 1.07 (0.84–1.37) | 12.5 | 28.0 | 0.186 | |
Never smokers |
n = 9 (2, 3, 10, 12, 27, 43, 48, 59, 72) | 1.72 (1.01–2.94) | 15.9 | 49.7 | 0.044 | |
Never smokers – alcohol adjusted |
n = 3 (2, 3, 12) | 1.87 (0.82–4.27) | 0.6 | 0.0 | 0.731 | |
Any (USA)d
| Overall data |
n = 31 (1, 2, 3, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 29, 30, 33, 34, 35, 38, 39, 41, 42, 46, 49, 51, 55, 56, 58, 65, 74) | 2.16 (1.55–3.02) | 275.8 | 89.1 | < 0.001 |
Smoking-adjusted |
n = 12 (2, 3, 13, 18, 26, 35, 43, 51, 55, 56, 58, 74) | 1.65 (1.22–2.25) | 33.6 | 67.3 | < 0.001 | |
Smoking and alcohol adjusted |
n = 6 (2, 3, 51, 55, 56, 74) | 1.04 (0.80–1.35) | 1.8 | 0.0 | 0.875 | |
Never smokers |
n = 5 (2, 3, 27, 43, 59) | 3.33 (1.76–6.32) | 3.5 | 0.0 | 0.476 | |
Never smokers – alcohol adjusted |
n = 2 (2, 3) | 1.58 (0.52–4.81) | 0.4 | 0.0 | 0.512 | |
Snuff (Scandinavia) | Overall data |
n = 7 (6, 7, 11, 48, 63, 69, 77) | 0.97 (0.68–1.37) | 14.5 | 58.8 | 0.024 |
Smoking-adjusted |
n = 7 (6, 7, 11, 48, 63, 69, 77) | 0.97 (0.68–1.37) | 14.5 | 58.8 | 0.024 | |
Smoking and alcohol adjusted |
n = 4 (11, 63, 69, 77) | 1.10 (0.64–1.90) | 10.7 | 71.9 | 0.014 | |
Never smokers |
n = 4 (10, 12, 48, 72) | 1.01 (0.71–1.45) | 2.2 | 0.0 | 0.524 | |
Never smokers – alcohol adjusted |
n = 1 (12) | 2.30 (0.67–7.92) | -- | -- | -- | |
Published since 1990 | Overall data |
n = 18 (1, 2, 3, 6, 7, 11, 48, 49, 51, 55, 56, 58, 60, 63, 65, 73, 74, 77) | 1.28 (0.94–1.76) | 81.7 | 79.2 | < 0.001 |
Smoking-adjusted |
n = 14 (2, 3, 6, 7, 11, 48, 51, 55, 56, 58, 63, 69, 74, 77) | 1.00 (0.83–1.20) | 18.5 | 29.8 | 0.139 | |
Smoking and alcohol adjusted |
n = 10 (2, 3, 11, 51, 55, 56, 63, 69, 74, 77) | 1.07 (0.84–1.37) | 12.5 | 28.0 | 0.186 | |
Never smokers |
n = 7 (2, 3, 10, 12, 48, 59, 72) | 1.24 (0.80–1.90) | 7.5 | 20.1 | 0.277 | |
Never smokers – alcohol adjusted |
n = 3 (2, 3, 12) | 1.87 (0.82–4.27) | 0.6 | 0.0 | 0.731 |
Oesophageal cancer
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sexd
| Id. | Casese
| Estimate (95%CI)d
| Adjustment factorsf
|
Cohort studies
| ||||||||
Lutheran Brotherhood: IARC Monograph 37 1985 [14] | ST | Ever | Any | M | 1 | NA | 2.6 (not significant) | age, res |
US Veterans: Winn et al. 1982 [19] | ST | Ever | Never | Mg
| 2 | 1 | 2.28 (NA) | age |
Norway cohorts: Boffetta et al. 2005 [26] | Snuff | Current | Any | M | 3 | 4 | 1.06 (0.35–3.23) | age, smok |
Former | M | 4 | 5 | 1.90 (0.69–5.27) | ||||
Ever | M | 5 | 9 | 1.40 (0.61–3.24) | ||||
Swedish construction workers: Zendehdel et al. 2008 [34] | Snuff | Ever | Any | M | 6 | 77 | 1.00 (0.79–1.27)h
| age, bmi, smok |
Never | 7 | 11 | 1.92 (1.00–3.68)i
| age, bmi | ||||
Case-control studies
| ||||||||
Wynder et al. 1957 [40] | Chew | Ever | Any | M | 8 | NA | no associationj
| none |
Wynder and Bross 1961 [44] | Chew | Ever | Any | M | 9 | 21 | 2.39 (1.23–4.64)k
| none |
Martinez et al. 1969 [49] | Chew | Use | Never | M | 10 | 3 | 1.18 (0.28–4.90)k
| none |
F | 11 | 7 | 2.69 (0.92–7.87)k
| |||||
Bjelke et al. 1974 USA [52] | Chew | Use | NA | NA | 12 | NA | associationl
| NA |
Williams and Horm 1977 [55] | ST | Ever | Any | M | 13 | 2 | 0.55 (0.13–2.31) | none |
Wynder and Stellman 1977 [56] | Chew | Ever | Any | M | 14 | 20 | 1.23 (0.76–1.99)k
| none |
Snuff | 15 | 8 | 1.65 (0.78–3.49)k
| |||||
ST | 16 | 28 | 1.35 (0.89–2.06)m
| |||||
Pottern et al. 1981 [60] | Chew | Ever | Any | M | 17 | 4 | no associationn
| none |
Snuff | 18 | 2 | no associationn
| |||||
Morris Brown et al. 1988 [76] | ST | Ever | Never | M | 19 | 1 | 1.20 (0.10–13.30) | alc, incm |
Lewin et al. 1998 [102] | Snuff | Current | Any | M | 20 | 10 | 1.10 (0.50–2.40) | age, alc, res, smok |
Former | 21 | 9 | 1.30 (0.60–3.10) | |||||
Ever | 22 | 19 | 1.20 (0.70–2.20) | |||||
Lagergren et al. 2000 [108] | Snuff | Ever | Any | M+F | 23 | 68 | 1.31 (0.89–1.92)k
| age, alc, bmi, diet, edu, exer, rflx, sex, smok |
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any | Overall data | 10 (5, 6, 9, 10, 11, 13, 16, 19, 22, 23) | 1.25 (1.03–1.51) | 10.3 | 13.0 | 0.324 |
Smoking-adjusted | 7 (5, 6, 10, 11, 19, 22, 23) | 1.13 (0.95–1.36) | 4.4 | 0.0 | 0.623 | |
Never smokers | 4 (7, 10, 11, 19) | 1.91 (1.15–3.17) | 1.0 | 0.0 | 0.810 | |
Any (USA)d
| Overall data | 6 (9, 10, 11, 13, 16, 19) | 1.56 (1.11–2.19) | 5.2 | 4.6 | 0.387 |
Smoking-adjusted | 3 (10, 11, 19) | 1.89 (0.84–4.25) | 1.0 | 0.0 | 0.617 | |
Never smokers | 3 (10, 11, 19) | 1.89 (0.84–4.25) | 1.0 | 0.0 | 0.617 | |
Snuff (Scandinavia) | Overall data | 4 (5, 6, 22, 23) | 1.10 (0.92–1.33) | 1.8 | 0.0 | 0.61 |
Smoking-adjusted | 4 (5, 6, 22, 23) | 1.10 (0.92–1.33) | 1.8 | 0.0 | 0.61 | |
Never smokers | 1 (7) | 1.92 (1.00–3.68) | -- | -- | -- |
Stomach cancer
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sexd
| Id. | Casese
| Estimate (95%CI)d
| Adjustment factorsf
|
Cohort studies
| ||||||||
Lutheran Brotherhood: Kneller et al. 1991 [12] | ST | Ever | Any | M | 1 | 18 | 1.60 (0.58–4.50) | age, byr, smok |
Never | M | 2 | 3 | 3.80 (1.00–14.32) | age, byr | |||
US Veterans: Winn et al. 1982 [19] | ST | Ever | Never | Mg
| 3 | NA | 1.51 (NA) | age |
CPS-II: Chao et al. 2002 [24] | ST | Current | Never | M | 4 | 8 | 1.58 (0.76–3.28) | age, asp, diet, edu, fhis, race, vit |
Former | 5 | 2 | 1.11 (0.27–4.50) | |||||
Ever | 6 | 10 | 1.45 (0.75–2.80)h
| |||||
Norway cohorts: Boffetta et al. 2005 [26] | Snuff | Current | Any | M | 7 | 42 | 1.00 (0.71–1.42) | age, smok |
Former | 8 | 32 | 1.29 (0.87–1.91) | |||||
Ever | 9 | 74 | 1.11 (0.83–1.48) | |||||
Swedish construction workers: Zendehdel et al. 2008 [34] | Snuff | Ever | Any | M | 10 | 311 | 1.08 (0.96–1.22)i
| age, bmi, smok |
Ever | Never | M | 11 | 76 | 1.33 (1.03–1.72)j
| age, bmi | ||
Case-control studies
| ||||||||
Bjelke 1974 (USA) [52] | Chew | Use | Any | NA | 12 | NA | no association | NA |
Bjelke 1974 (Norway) [52] | Chew | Use | Any | NA | 13 | NA | association | NA |
Williams and Horm 1977 [55] | ST | Ever | Any | M | 14 | 12 | 1.31 (0.71–2.43)h
| age, race, smok |
F | 15 | 2 | 1.50 (0.36–6.26) | none | ||||
Weinberg et al. 1985 [67] | Chew | Ever | Any | M | 16 | NA | no association | none |
Hansson et al. 1994 [94] | Snuff | Use | Any | M+F | 17 | NA | 0.70 (0.47–1.06) | age, ses, sex, smok |
Ye et al. 1999 [107] | Chew | Ever | Any | M+F | 18 | 8 | 1.30 (0.54–3.12)h
| none |
Snuff | Ever | M | 19 | 83 | 0.77 (0.56–1.06)h
| age, alc, bmi, res, ses, smok | ||
Never | M | 20 | 11 | 0.50 (0.20–1.20) | age, alc, bmi, res, ses | |||
Lagergren et al. 2000 [108] | Snuff | Ever | Any | M+F | 21 | 53 | 1.20 (0.80–1.80) | age, alc, bmi, diet, edu, exer, rflx, sex, smok |
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any | Overall data | 9 (1, 6, 9, 10, 14, 15, 17, 19, 21) | 1.03 (0.90–1.19) | 10.5 | 24.0 | 0.230 |
Smoking-adjusted | 8 (1, 6, 9, 10, 14, 17, 19, 21) | 1.03 (0.88–1.20) | 10.3 | 31.9 | 0.173 | |
Never smokers | 4 (2, 6, 11, 20) | 1.27 (0.75–2.13) | 7.0 | 57.2 | 0.072 | |
Any (USA) | Overall data | 4 (1, 6, 14, 15) | 1.41 (0.95–2.10) | 0.1 | 0.0 | 0.988 |
Smoking-adjusted | 3 (1, 6, 14) | 1.41 (0.93–2.12) | 0.1 | 0.0 | 0.942 | |
Never smokers | 2 (2, 6) | 1.96 (0.82–4.70) | 1.6 | 38.2 | 0.203 | |
Snuff (Scandinavia) | Overall data | 5 (9, 10, 17, 19, 21) | 0.98 (0.82–1.17) | 8.1 | 50.4 | 0.089 |
Smoking-adjusted | 5 (9, 10, 17, 19, 21) | 0.98 (0.82–1.17) | 8.1 | 50.4 | 0.089 | |
Never smokers | 2 (11, 20) | 0.90 (0.35–2.30) | 4.2 | 76.4 | 0.040 |
Pancreatic cancer
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sex | Id. | Casesd
| Estimate (95%CI)e
| Adjustment factorsf
|
Cohort studies
| ||||||||
Lutheran Brotherhood: Zheng et al. 1993 [13] | ST | Ever | Any | M | 1 | 16 | 1.70 (0.90–3.10) | age, alc, smok |
US Veterans: Winn et al. 1982 [19] | ST | Ever | Never | Mg
| 2 | NA | 1.65 (NA) | age |
Norway cohorts: Boffetta et al. 2005 [26] | Snuff | Current | Any | M | 3 | 27 | 1.60 (1.00–2.55) | age, smok |
Former | 4 | 18 | 1.80 (1.04–3.09) | |||||
Ever | 5 | 45 | 1.67 (1.12–2.50) | |||||
Ever | Never | 6 | 3 | 0.85 (0.24–3.07) | age | |||
Swedish construction workers: Luo et al. 2007 [32] | Snuff | Ever | Any | M | 7 | NA | 0.90 (0.70–1.20) | age, bmi, smok |
Current | Never | 8 | 18 | 2.10 (1.20–3.60) | age, bmi | |||
Former | 9 | 2 | 1.40 (0.40–5.90) | |||||
Ever | 10 | 20 | 2.00 (1.20–3.30) | |||||
Case-control studies
| ||||||||
Williams and Horm 1977[55] | ST | Ever | Any | M | 11 | 3 | 0.29 (0.09–0.92)h
| age, race, smok |
Falk et al. 1988 [75] | Chew | Use | Any | M+F | 12 | NA | no association | none |
Snuff | 13 | NA | no association | |||||
Farrow and Davis 1990 [82] | Chew | Ever | Any | M | 14 | NA | 0.80 (NA) | edu, race |
Ghadirian et al. 1991[84] | Chew | Use | Any | M+F | 15 | NA | no association | none |
Muscat et al. 1997 [101] | Chew | Ever | Neveri
| M | 16 | 6 | 2.82 (0.85–9.39)j
| none |
Snuff | Any | 17 | 2 | 1.32 (0.22–7.93) | ||||
Alguacil and Silverman 2004 [111] | ST | Ever | Neverk
| M+F | 18 | 5 | 1.10 (0.40–3.10) | age, race, res, sex, smokk
|
Hassan et al. 2007 [114] | Chew | Ever | Any | M+F | 19 | 34 | 0.70 (0.40–1.10) | age, alc, diab, edu, mar, race, res, sex, smok |
Never | 20 | 10 | 0.60 (0.30–1.40) | age, alc, diab, edu, mar, race, res, sex | ||||
Snuff | Ever | Any | 21 | 18 | 0.60 (0.30–1.10) | age, alc, diab, edu, mar, race, res, sex, smok | ||
Never | 22 | 4 | 0.50 (0.10–1.50) | age, alc, diab, edu, mar, race, res, sex | ||||
ST | Ever | Any | 23 | 52 | 0.65 (0.43–0.97)l
| age, alc, diab, edu, mar, race, res, sex, smok | ||
Never | 24 | 14 | 0.57 (0.29–1.11)l
| age, alc, diab, edu, mar, race, res, sex |
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any | Overall data | 7 (1, 5, 7, 11, 17, 18, 23) | 1.00 (0.68–1.47) | 18.5 | 67.5 | 0.005 |
Smoking-adjusted | 7 (1, 5, 7, 11, 16, 18, 23) | 1.07 (0.71–1.60) | 21.2 | 71.7 | 0.002 | |
Never smokers | 5 (6, 10, 16, 18, 24) | 1.23 (0.66–2.31) | 10.7 | 62.7 | 0.030 | |
Any (USA) | Overall data | 5 (1, 11, 17, 18, 23) | 0.86 (0.47–1.57) | 10.2 | 61.0 | 0.037 |
Smoking-adjusted | 5 (1, 11, 16, 18, 23) | 0.99 (0.51–1.91) | 13.8 | 71.0 | 0.008 | |
Never smokers | 3 (16, 18, 24) | 1.09 (0.44–2.67) | 5.4 | 63.0 | 0.067 | |
Snuff (Scandinavia) | Overall data | 2 (5, 7) | 1.20 (0.66–2.20) | 6.3 | 84.1 | 0.012 |
Smoking-adjusted | 2 (5, 7) | 1.20 (0.66–2.20) | 6.3 | 84.1 | 0.012 | |
Never smokers | 2 (6, 10) | 1.61 (0.77–3.34) | 1.5 | 33.2 | 0.221 |
Other cancers of the digestive system
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sexd
| Id. | Casese
| Estimate (95%CI)d
| Adjustment factorsf
|
Cohort studies
| ||||||||
US Veterans: Heineman et al. 1995 [18] | ||||||||
- colon cancer | ST | Ever | Never | Mg
| 1 | 39 | 1.20 (0.90–1.70)h
| age, sed, ses, time, yriv |
- rectal cancer | Never | 2 | 17 | 1.90 (1.20–3.10)h
| ||||
US Veterans: Winn et al. 1982 [19] | ||||||||
- liver cancer | ST | Ever | Never | Mg
| 3 | NA | 2.81 (NA) | age |
NHANES I: Accortt et al. 2005 [22] | ||||||||
- digestive cancer | ST | Ever | Never | M | 4 | 13 | 0.80 (0.40–1.80) | age, pov, race |
F | 5 | 4 | 0.80 (0.30–2.40) | |||||
CPS-I: Henley et al. 2005 [23] | ||||||||
- digestive cancer | ST | Current | Never | M | 6 | 153 | 1.26 (1.05–1.52) | age, alc, asp, bmi, diet, edu, exer, occ, race |
CPS-II: Henley et al. 2005 [23] | ||||||||
- digestive cancer | ST | Current | Never | M | 7 | 48 | 1.04 (0.77–1.38) | age, alc, asp, bmi, diet, edu, exer, occ, race |
Former | 8 | 19 | 0.99 (0.63–1.57) | |||||
Ever | 9 | 67 | 1.03 (0.80–1.31)h
| |||||
Case-control studies
| ||||||||
Bjelke 1974 [52] USA | ||||||||
- colorectal cancer | Chew | Use | Any | NA | 10 | NA | No association | NA |
Bjelke 1974 [52] Norway | ||||||||
- colorectal cancer | Chew | Use | Any | NA | 11 | NA | No association | NA |
Williams and Horm 1977 [55] | ||||||||
- small intestine cancer | ST | Ever | Any | M | 12 | 2 | 3.11 (0.65–14.8)h
| age, race, smok |
- colon cancer | ST | Ever | Any | M | 13 | 30 | 1.36 (0.90–2.07)h
| age, race, smok |
F | 14 | 7 | 1.28 (0.58–2.87)h
| |||||
- rectal cancer | ST | Ever | Any | M | 15 | 13 | 0.75 (0.42–1.35)h
| age, race, smok |
F | 16 | 2 | 0.87 (0.21–3.62)h
| |||||
- liver cancer | ST | Ever | Any | M | 17 | 1 | 0.58 (0.08–4.39)h
| none |
- gall bladder cancer | ST | Ever | Any | M | 18 | 1 | 0.41 (0.05–3.04)h
| none |
Sterling et al. 1992 [89] | ||||||||
- digestive cancer | ST | Ever | Any | M+F | 19 | 555 | 0.40 (0.24–0.69)h
| age, alc, occ, race, sex, smok |
Chow et al. 1994 [93] | ||||||||
- bile duct canceri
| Chew | Use | Any | M | 20 | 3 | 18.0 (1.40–227.70) | NA |
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any (USA)d
| Overall data | 5 (4, 5, 6, 9, 19) | 0.86 (0.59–1.25) | 17.3 | 76.9 | 0.002 |
Smoking-adjusted | 5 (4, 5, 6, 9, 19) | 0.86 (0.59–1.25) | 17.3 | 76.9 | 0.002 | |
Never smokers | 4 (4, 5, 6, 9) | 1.14 (0.99–1.33) | 3.1 | 2.1 | 0.382 |
Larynx and nasal cancer
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sex | Id. | Casesd
| Estimate (95%CI) | Adjustment factorse
|
Case-control studies
| ||||||||
Wynder et al. 1957 [40] | ||||||||
- larynx cancer | Chew | Ever | Any | M | 1 | NA | no associationf
| none |
Vincent and Marchetta 1963 [45] | ||||||||
- larynx cancer | Snuff | Use | Any | M | 2 | 5 | 1.81 (0.33–9.97) | none |
Williams and Horm 1977 [55] | ||||||||
- larynx cancer | ST | Ever | Any | M | 3 | 16 | 2.01 (1.15–3.51)g
| age, race, smok |
Wynder and Stellman 1977 [56] | ||||||||
- larynx cancer | Chew | Ever | Any | M | 4 | 46 | 1.35 (0.96–1.89)g
| none |
Snuff | 5 | 15 | 1.46 (0.82–2.57)g
| none | ||||
ST | 6 | 61 | 1.40 (1.04–1.89)h
| none | ||||
Engzell et al. 1978 [57] | ||||||||
- nasal cancer | Snuff | Use | Any | M | 7 | NA | no association | none |
Brinton et al. 1984 [64] | ||||||||
- nasal cancer | Chew | Use | Any | M+F | 8 | 15 | 0.74 (0.40–1.50) | sex |
Snuff | 9 | 23 | 1.47 (0.80–2.80) | |||||
ST | 10 | 38 | 1.08 (0.68–1.70)h
| none | ||||
Stockwell and Lyman 1986 [70] | ||||||||
- nasal cancer | ST | Ever | Any | M+F | 11 | 1 | 2.93 (0.40–21.66)g
| none |
- larynx cancer | ST | Ever | Any | M+F | 12 | 6 | 2.02 (0.84–4.86)g
| none |
Young et al. 1986 [71] | ||||||||
- larynx cancer | ST | Ever | Any | M | 13 | NA | no association | none |
Lewin et al. 1998 [102] | ||||||||
- larynx cancer | Snuff | Current | Any | M | 14 | 15 | 1.00 (0.50–1.90) | age, alc, res, smok |
Former | 15 | 9 | 0.80 (0.40–1.70) | |||||
Ever | 16 | 24 | 0.90 (0.50–1.50) |
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Larynx cancer
d
| ||||||
Any | Overall data | 5 (2, 3, 6, 12, 16) | 1.43 (1.08–1.89) | 4.8 | 17.4 | 0.304 |
Smoking-adjusted | 2 (3, 16) | 1.34 (0.61–2.95) | 4.0 | 75.3 | 0.044 | |
Any (USA) | Overall data | 4 (2, 3, 6, 12) | 1.56 (1.21–2.00) | 1.7 | 0.0 | 0.646 |
Smoking-adjusted | 1 (3) | 2.01 (1.15–3.51) | -- | -- | -- | |
Snuff (Scandinavia) | Overall data | 1 (16) | 0.90 (0.50–1.50) | -- | -- | -- |
Smoking-adjusted | 1 (16) | 0.90 (0.50–1.50) | -- | -- | -- | |
Nasal cancer
e
| ||||||
Any | Overall data | 2 (10, 11) | 1.14 (0.73–1.77) | 0.9 | 0.0 | 0.339 |
Lung cancer
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sex | Id. | Casesd
| Estimate (95%CI)e
| Adjustment factorsf
|
Cohort studies
| ||||||||
US Veterans: Winn et al. 1982 [19] | ST | Ever | Never | Mg
| 1 | NA | 0.60 (NA) | age |
NHANES I: Accortt et al. 2005 [22] | ST | Ever | Never | F | 2 | 4 | 6.80 (1.60–28.5) | age, pov, race |
CPS-I: Henley et al. 2005 [23] | ST | Current | Never | M | 3 | 18 | 1.08 (0.64–1.83) | age, alc, asp, bmi, diet, edu, exer, occ, race |
CPS-II: Henley et al. 2005 [23] | ST | Current | Never | M | 4 | 18 | 2.00 (1.23–3.24) | age, alc, asp, bmi, diet, edu, exer, occ, race |
ST | Former | 5 | 4 | 1.17 (0.43–3.14) | ||||
ST | Ever | 6 | 22 | 1.77 (1.14–2.74)h
| ||||
Chew only | Current | 7 | 12 | 1.97 (1.10–3.54) | ||||
Snuff only | 8 | 2 | 2.08 (0.51–8.46) | |||||
Norway cohorts: Boffetta et al. 2005 [26] | Snuff | Current | Any | M | 9 | 44 | 0.80 (0.58–1.11) | age, smok |
Former | 10 | 28 | 0.80 (0.54–1.19) | |||||
Ever | 11 | 72 | 0.80 (0.61–1.05) | |||||
Ever | Never | 12 | 3 | 0.96 (0.26–3.56) | age | |||
Swedish construction workers: Luo et al. 2007 [32] | Snuff | Ever | Any | M | 13 | NA | 0.70 (0.60–0.70) | age, bmi, smok |
Current | Never | 14 | 15 | 0.80 (0.40–1.30) | age, bmi | |||
Former | 15 | 3 | 0.90 (0.30–3.00) | |||||
Ever | 16 | 18 | 0.80 (0.50–1.30) | |||||
Case-control studies
| ||||||||
Doll and Hill 1952 [38] | Chew | Ever | Any | M | 17 | 40 | 0.61 (0.41–0.92)h
| none |
Snuff | 18 | 33 | 0.76 (0.48–1.21)h
| |||||
ST | 19 | 73 | 0.66 (0.41–0.90)h
| |||||
Williams and Horm 1977 [55] | ST | Ever | Any | M | 20 | 36 | 0.69 (0.47–1.00)h
| age, race, smok |
F | 21 | 1 | 0.38 (0.05–2.80)h
| none | ||||
Wynder and Stellman 1977 [56] | Chew | Ever | Any | M | 22 | 117 | 1.26 (0.99–1.59)h
| none |
Snuff | 23 | 35 | 1.25 (0.83–1.89)h
| |||||
ST | 24 | 152 | 1.27 (1.03–1.57)h
|
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any | Overall data | 9 (2, 3, 6, 11, 13, 19, 20, 21, 24) | 0.96 (0.73–1.27) | 53.2 | 85.0 | < 0.001 |
Smoking-adjusted | 6 (2, 3, 6, 11, 13, 20) | 0.99 (0.71–1.37)d
| 28.7 | 82.6 | < 0.001 | |
Never smokers | 5 (2, 3, 6, 12, 16) | 1.34 (0.80–2.23) | 11.5 | 65.3 | 0.021 | |
Any (USA) | Overall data | 6 (2, 3, 6, 20, 21, 24) | 1.22 (0.82–1.83) | 18.5 | 73.0 | 0.002 |
Smoking-adjusted | 4 (2, 3, 6, 20) | 1.38 (0.72–2.64) | 16.5 | 81.9 | 0.001 | |
Never smokers | 3 (2, 3, 6) | 1.79 (0.91–3.51) | 6.2 | 67.8 | 0.045 | |
Snuff (Scandinavia) | Overall data | 2 (11, 13) | 0.71 (0.66–0.76) | 0.9 | 0.0 | 0.354 |
Smoking-adjusted | 2 (11, 13) | 0.71 (0.66–0.76) | 0.9 | 0.0 | 0.354 | |
Never smokers | 2 (12, 16) | 0.82 (0.52–1.28) | 0.1 | 0.0 | 0.798 |
Prostate cancer
ST use | RR/OR | ||||||
---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Id. | Casesd
| Estimate (95%CI) | Adjustment factorse
|
Cohort studies
| |||||||
Lutheran Brotherhood: Hsing et al. 1990 [11] | ST | Ever | Any | 1 | 38 | 1.51 (1.03–2.19)f
| age, smok |
Never | 2 | 10 | 4.50 (2.10–9.70) | age | |||
US Veterans: Hsing et al. 1991 [15] | ST | Ever | Never | 3 | 48 | 1.17 (0.88–1.56) | age |
Iowa cohort: Putnam et al. 2000 [20] | ST | Ever | Any | 4 | NA | no association | age |
NHANES I: Accortt et al. 2005 [22] | ST | Ever | Never | 5 | 19 | 1.20 (0.50–3.40) | age, pov, race |
Norway cohorts: IARC Monograph 37 1985 [14] | ST | Use | Any | 6 | NA | no association | age, res, smok |
Case-control studies
| |||||||
Williams and Horm 1977 [55] | ST | Ever | Any | 7 | 65 | 1.32 (0.94–1.84)f
| age, race, smok |
Hayes et al. 1994 [96] | Chew | Current | Any | 8 | 14 | 0.56 (0.30–1.06)f
| none |
Former | 9 | 56 | 1.08 (0.75–1.55)f
| ||||
Ever | 10 | 70 | 0.91 (0.67–1.25)f
| ||||
Snuff | Current | Any | 11 | 10 | 6.74 (1.47–30.84)f
| ||
Former | 12 | 10 | 0.79 (0.36–1.74)f
| ||||
Ever | 13 | 20 | 1.42 (0.75–2.67)f
| ||||
ST | Current | Any | 14 | 24 | 0.92 (0.54–1.58)g
| ||
Former | 15 | 66 | 1.03 (0.74–1.43)g
| ||||
Ever | 16 | 90 | 1.00 (0.75–1.33)g
|
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Anyd
| Overall data | 5 (1, 3, 5, 7, 16) | 1.20 (1.03–1.40) | 3.3 | 0.0 | 0.506 |
Smoking-adjusted | 4 (1, 3, 5, 7) | 1.29 (1.07–1.55) | 1.2 | 0.0 | 0.764 | |
Never smokers | 3 (2, 3, 5) | 1.81 (0.76–4.30) | 10.5 | 81.0 | 0.005 |
Bladder cancer
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sex | Id. | Casesd
| Estimate (95%CI) | Adjustment factorse
|
Cohort studies
| ||||||||
Norway cohorts: Boffetta et al. 2005 [26] | Snuff | Current | Any | M | 1 | 40 | 0.72 (0.52–1.06) | age, smok |
Former | 2 | 30 | 0.98 (0.66–1.47) | |||||
Ever | 3 | 69 | 0.83 (0.62–1.11) | |||||
Case-control studies
| ||||||||
Lockwood 1961 [43] | ST | Current | Never | M | 4 | 2 | 0.35 (0.07–1.77)f
| none |
Wynder et al. 1963 [46] | Chew | Ever | Any | M | 5 | 33 | 1.42 (0.82–2.47)f
| none |
Snuff | 6 | 6 | 0.66 (0.23–1.88)f
| |||||
ST | 7 | 39 | 1.21 (0.74–1.98)g
| |||||
Dunham et al. 1968 [48] | ST | Ever | Never | M | 8 | 4 | 2.57 (0.52–12.54)f
| race |
F | 9 | 3 | 0.58 (0.14–2.45)f
| |||||
Cole et al. 1971 [51] | Chew | Ever | Any | M | 10 | 46 | no associationh
| age |
Snuff | 11 | 3 | no associationi
| |||||
Williams and Horm 1977 [55] | ST | Ever | Any | M | 12 | 29 | 1.67 (1.09–2.55)f
| age, race, smok |
F | 13 | 1 | 0.82 (0.11–6.02)f
| none | ||||
Wynder and Stellman 1977 [56] | Chew | Ever | Any | M | 14 | 47 | 0.87 (0.63–1.21)f
| none |
Snuff | 15 | 11 | 0.69 (0.36–1.31)f
| |||||
ST | 16 | 58 | 0.82 (0.61–1.10)g
| |||||
Howe et al. 1980 [58] | Chew | Ever | Any | M | 17 | NA | 0.90 (0.50–1.60) | age, smok |
Mommsen and Aagaard 1983 [62] | Chew | Ever | Any | M | 18 | 39 | 1.70 (1.00–2.90) | age, res |
Hartge et al. 1985 [66] | Chew | Ever | Neverj
| M | 19 | 40 | 1.02 (0.67–1.54) | age, race, res, smokj
|
Snuff | 20 | 11 | 0.77 (0.38–1.56) | |||||
ST | 21 | 51 | 1.14 (0.80–1.61)g
| none | ||||
Kabat et al. 1986 [69] | Snuff | Ever | Never | F | 22 | 3 | 10.40 (1.07–101.46) | none |
Slattery et al. 1988 [77] | Chew | Ever | Any | M | 23 | 20 | 0.76 (0.42–1.39) | smokk
|
Never | 24 | 1 | 0.36 (0.05–2.82)l
| none | ||||
Snuff | Ever | Any | 25 | 16 | 0.92 (0.47–1.82) | smokk
| ||
Never | 26 | 2 | 2.74 (0.45–16.69)m
| none | ||||
ST | Ever | Any | 27 | 36 | 0.82 (0.52–1.29)g
| smokk
| ||
Never | 28 | 3 | 0.86 (0.24–3.07)g
| none | ||||
Burch et al. 1989 [79] | Chew | Ever | Any | M | 29 | 26 | 0.60 (0.34–1.06) | age, res, smok |
Snuff | 30 | 9 | 0.47 (0.21–1.07) | |||||
ST | 31 | 35 | 0.54 (0.34–0.87)g
|
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any | Overall data | 14 (3, 4, 7, 8, 9, 12, 13, 16, 17, 18, 21, 22, 27, 31) | 1.00 (0.80–1.25) | 28.7 | 54.7 | 0.007 |
Smoking-adjusted | 10 (3, 4, 8, 9, 12, 17, 21, 22, 27, 31) | 0.95 (0.71–1.29) | 22.3 | 59.6 | 0.008 | |
Never smokers | 6 (4, 8, 9, 21, 22, 28) | 1.10 (0.60–2.02) | 7.7 | 35.1 | 0.173 | |
Any (USA) | Overall data | 9 (7, 8, 9, 12, 13, 16, 21, 22, 27) | 1.11 (0.85–1.45) | 14.8 | 45.9 | 0.064 |
Smoking-adjusted | 6 (8, 9, 12, 21, 22, 27) | 1.24 (0.83–1.85) | 10.4 | 52.1 | 0.064 | |
Never smokers | 5 (8, 9, 21, 22, 28) | 1.25 (0.69–2.26) | 5.6 | 29.2 | 0.227 | |
Snuff (Scandinavia)d
| Overall data | 1 (3) | 0.83 (0.62–1.11) | -- | -- | -- |
Smoking-adjusted | 1 (3) | 0.83 (0.62–1.11) | -- | -- | -- |
Kidney cancer
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sex | Id. | Casesd
| Estimate (95%CI) | Adjustment factorse
|
Cohort studies
| ||||||||
Norway cohorts: Boffetta et al. 2005 [26] | Snuff | Current | Any | M | 1 | 9 | 0.47 (0.23–0.94) | age, smok |
Former | 2 | 13 | 1.17 (0.63–2.16) | |||||
Ever | 3 | 22 | 0.72 (0.44–1.18) | |||||
Case-control studies
| ||||||||
Bennington and Laubscher 1968 [47] | Chew | Use | Any | M | 4 | 5 | 1.22 (0.39–3.85)f
| none |
Never | 5 | 5 | 4.80 (1.18–19.59)f
| age | ||||
Armstrong et al. 1976 [53] | ST | Current | Any | M | 6 | 6 | 0.98 (0.30–3.15)f
| none |
Former | 7 | 6 | 0.73 (0.24–2.20)f
| |||||
Ever | 8 | 12 | 0.84 (0.37–1.92)f
| |||||
Williams and Horm 1977 [55] | ST | Ever | Any | M | 9 | 3 | 0.59 (0.18–1.90)f
| none |
F | 10 | 1 | 1.26 (0.17–9.33)f
| |||||
McLaughlin et al. 1984 [65] | Chew | Use | Any | M | 11 | NA | 0.40 (0.10–2.60) | age, smok |
Snuff | 12 | NA | 1.70 (0.50–6.00) | |||||
ST | 13 | NA | 1.00 (0.37–2.68)g
| |||||
Goodman et al. 1986 [68] | Chew | Ever | Any | M | 14h
| 13 | 4.00 (1.13 – 14.17) | age, hosp, race, tadm |
Asal et al. 1988 [73] | Snuff | Use | Any | M | 15i
| NA | 3.60 (1.20–13.30) | age, hosp, race, tadm |
16j
| NA | no association | age, race, tadm | |||||
McLaughlin et al. 1995 [99] | ST | Use | Never | M+F | 17 | 11 | 1.30 (0.60–3.10) | age, bmi, res, sex |
Muscat et al. 1995 [100] | Chew | Ever | Any | M | 18 | 14 | 3.20 (1.10–8.70) | age, edu |
Yuan et al. 1998 [106] | ST | Ever | Any | M+F | 19 | 32 | 1.02 (0.56–1.85) | age, edu, smok |
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any | Overall data | 11 (3, 4, 8, 9, 10, 13, 14, 15, 17, 18, 19) | 1.23 (0.86–1.76)d
| 16.5 | 39.2 | 0.087 |
Smoking-adjusted | 5 (3, 5, 13, 17, 19) | 1.09 (0.69–1.71)e
| 6.9 | 41.9 | 0.142 | |
Never smokers | 2 (5, 17) | 2.19 (0.63–7.70) | 2.5 | 59.6 | 0.116 | |
Any (USA) | Overall data | 8 (4, 9, 10, 13, 14, 15, 18, 19) | 1.52 (0.94–2.46) | 11.1 | 37.1 | 0.133 |
Smoking-adjusted | 3 (5, 13, 19) | 1.41 (0.64–3.10) | 4.2 | 51.8 | 0.125 | |
Never smokers | 1 (5) | 4.80 (1.18–19.56) | -- | -- | -- | |
Snuff (Scandinavia)f
| Overall data | 1 (3) | 0.72 (0.44–1.18) | -- | -- | -- |
Smoking-adjusted | 1 (3) | 0.72 (0.44–1.18) | -- | -- | -- |
Haematopoietic and lymphoid cancer
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sex | Id. | Casesd
| Estimate (95%CI) | Adjustment factorse
|
Cohort studies
| ||||||||
US veterans: Heinemann et al. 1992 [16] | ||||||||
- multiple myeloma | ST | Use | Never | Mf
| 1 | 6 | 1.00 (0.40–2.30) | age, time, yriv |
CPS-II: Henley et al. 2005 [23] | ||||||||
- any haematopoietic cancer | ST | Current | Never | M | 2 | 19 | 0.95 (0.60–1.51) | age, alc, asp, bmi, diet, edu, exer, occ, race |
Former | 3 | 9 | 1.16 (0.60–2.25) | |||||
Ever | 4 | 28 | 1.01 (0.69–1.48)g
| |||||
Swedish construction workers: Fernberg et al. 2006 [30] | ||||||||
- non-Hodgkin's lymphoma | Snuff | Ever | Never | M | 5 | 66 | 0.77 (0.59–1.01) | age, bmi |
- Hodgkin's disease | Snuff | Ever | Never | M | 6 | 15 | 0.88 (0.49–1.58) | |
Swedish construction workers: Fernberg et al. 2007 [31] | ||||||||
- leukaemia | Snuff | Ever | Never | M | 7 | NA | no increased risk | age, bmi |
- multiple myeloma | Snuff | Ever | Never | M | 8 | NA | no increased risk | age, bmi |
Case-control studies
| ||||||||
Williams and Horm 1977 [55] | ||||||||
- any haemopoietic cancer | ST | Ever | Any | M | 9 | 13 | 0.63 (0.35–1.14)g
| none |
F | 10 | 3 | 1.01 (0.31–3.29)g
| |||||
Lindquist et al. 1987 [72] | ||||||||
- leukaemia | Snuff | Ever | Any | M+F | 11 | 18 | 0.94 (0.47–1.89)h
| age, res, sex |
Morris Brown et al. 1992 [87] | ||||||||
- leukaemia | ST | Use | Never | M | 12 | 24 | 1.80 (0.90–3.30)i
| age, alc, res |
Morris Brown et al. 1992 [88] | ||||||||
- non-Hodgkin's lymphoma | ST | Use | Never | M | 13 | 19 | 1.30 (0.70–2.50)j
| age, res |
- multiple myeloma | ST | Use | Never | M | 14 | 5 | 1.90 (0.50–6.60) | age, res |
Hardell et al. 1994 [95] | ||||||||
- non-Hodgkin's lymphoma | Snuff | Use | Any | M | 15 | 35 | 1.50 (0.90–2.50) | none |
Schroeder et al. 2002 [110] | ||||||||
- non-Hodgkin's lymphoma | Chew | Ever | Any | M | 16 | 19 | 1.23 (0.80–1.88)k
| age, res |
Snuff | 17 | 19 | 0.93 (0.61–1.41)k
| |||||
ST | 18 | 38 | 1.06 (0.77–1.45)l
| |||||
Bracci and Holly 2005 [112] | ||||||||
- non-Hodgkin's lymphoma | ST | Ever | Never | M | 19 | 7 | 4.00 (1.30–12.00) | age, alc, edu |
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any | Overall data | 5 (5, 13, 15, 18, 19) | 1.20 (0.83–1.75)d
| 12.8 | 68.8 | 0.012 |
Smoking-adjusted | 3 (5, 13, 19) | 1.35 (0.62–2.94) | 9.5 | 78.9 | 0.009 | |
Never smokers | 3 (5, 13, 19) | 1.35 (0.62–2.94) | 9.5 | 78.9 | 0.009 | |
Any (USA) | Overall data | 3 (13, 18, 19) | 1.45 (0.81–2.59) | 5.2 | 61.2 | 0.076 |
Smoking-adjusted | 2 (13, 19) | 2.07 (0.70–6.13) | 3.0 | 66.2 | 0.085 | |
Never smokers | 2 (13, 19) | 2.07 (0.70–6.13) | 3.0 | 66.2 | 0.085 | |
Snuff (Scandinavia) | Overall data | 2 (5, 15) | 1.04 (0.54–1.98) | 5.1 | 80.5 | 0.024 |
Smoking-adjusted | 1 (5) | 0.77 (0.59–1.01) | -- | -- | -- | |
Never smokers | 1 (5) | 0.77 (0.59–1.01) | -- | -- | -- |
Other cancers
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sex | Id. | Casesd
| Estimate (95%CI) | Adjustment factorse
|
Cohort studies
| ||||||||
US Veterans: Zahm et al. 1992 [17] | ||||||||
- soft tissue sarcoma | ST | Ever | Any | Mf
| 1 | 21 | 0.85 (0.53–1.36) | age, smok, time |
NHANES I: Accortt et al. 2005 [22] | ||||||||
- breast cancer | ST | Ever | Never | F | 2 | 5 | 1.80 (0.50–6.50) | age, pov, race |
CPS-I: Henley et al. 2005 [23] | ||||||||
- genitourinary cancer | ST | Current | Never | M | 3 | 98 | 0.97 (0.77–1.22) | age, alc, asp, bmi, diet, edu, exer, occ, race |
CPS-II: Henley et al. 2005 [23] | ||||||||
- genitourinary cancer | ST | Current | Never | M | 4 | 44 | 1.15 (0.85–1.56) | age, alc, asp, bmi, diet, edu, exer, occ, race |
Former | 5 | 16 | 0.97 (0.59–1.59) | |||||
Ever | 6 | 60 | 1.10 (0.84–1.42)g
| |||||
Swedish construction workers: Odenbro et al. 2005 [29] | ||||||||
- cutaneous squamous cell carcinoma | Snuff | Ever | Any | M | 7 | 29 | 0.64 (0.44–0.95) | age, smok |
Swedish construction workers: Odenbro et al. 2007 [33] | ||||||||
- melanomah
| Snuff | Ever | Never | M | 8 | 96 | 0.65 (0.52–0.82) | age, bir, bmi |
Uppsala County: Roosaar et al. 2008 [35] | ||||||||
- smoking related cancer | Snuff | Ever | Any | M | 9 | 71 | 1.10 (0.80–1.40) | age, alc, res, smok, time |
Never | 10 | 39 | 1.60 (1.10–2.50) | age, alc, res, time | ||||
Case-control studies
| ||||||||
Moore et al. 1953 [39] | ||||||||
- cancer of face | ST | Use | Any | M | 11 | 49 | 2.41 (1.09–5.35) | none |
Williams and Horm 1977 [55] | ||||||||
- breast cancer | ST | Ever | Any | F | 12 | 11 | 0.60 (0.31–1.17)g
| age, smok |
- cancer of male genitalia | ST | Ever | Any | M | 13 | 2 | 0.47 (0.11–1.94)g
| None |
- cancer of cervix | ST | Ever | Any | F | 14 | 10 | 4.18 (2.08–8.43)g
| age, smok |
- cancer of uterus | ST | Ever | Any | F | 15 | 7 | 1.92 (0.86–4.28)g
| age, smok |
- cancer of ovary | ST | Ever | Any | F | 16 | 2 | 0.77 (0.19–3.21)g
| none |
- cancer of vulva | ST | Ever | Any | F | 17 | 1 | 2.06 (0.28–15.41)g
| none |
- connective tissue | ST | Ever | Any | M | 18 | 1 | 0.26 (0.04–1.93)g
| none |
- melanoma | ST | Ever | Any | M | 19 | 1 | 0.30 (0.04–2.18)g
| none |
- nervous system cancer | ST | Ever | Any | M | 20 | 1 | 0.18 (0.02–1.32)g
| none |
F | 21 | 2 | 3.28 (0.77–13.99)g
| |||||
- thyroid cancer | ST | Ever | Any | M | 22 | 1 | 0.36 (0.05–2.69)g
| none |
F | 23 | 1 | 0.73 (0.10–5.38)g
| |||||
Zahm et al. 1989 [81] | ||||||||
- soft tissue sarcoma | ST | Ever | Any | M | 24 | 28 | 1.80 (1.10–2.90) | Age |
Zheng et al. 2001 [109] | ||||||||
- brain cancer (glioma) | Chew | Use | Any | M+F | 25 | NA | no association | NA |
Snuff | 26 | NA | no association |
Overall cancer risk
ST use | RR/OR | |||||||
---|---|---|---|---|---|---|---|---|
Sourcea
| Typeb
| Exposurec
| Smoking | Sex | Id. | Casesd
| Estimate (95%CI)d
| Adjustment factorse
|
Cohort studies
| ||||||||
NHANES I: Accortt et al. 2005 [22] | ST | Ever | Never | M | 1 | 38 | 0.80 (0.40–1.60) | age, pov, race |
F | 2 | 26 | 1.20 (0.70–2.10) | age, pov, race | ||||
CPS-I: Henley et al. 2005 [23] | ST | Current | Never | M | 3 | 357 | 1.07 (0.95–1.20) | age, alc, asp, bmi, diet, edu, exer, occ, race |
CPS-II: Henley et al. 2005 [23] | ST | Current | Never | M | 4 | 162 | 1.19 (1.02–1.40) | age, alc, asp, bmi, diet, edu, exer, occ, race |
ST | Former | 5 | 57 | 1.04 (0.80–1.36) | ||||
ST | Ever | 6 | 219 | 1.15 (1.00–1.32)f
| ||||
Chew only | Current | 7 | 113 | 1.23 (1.02–1.49) | ||||
Snuff only | Current | 8 | 14 | 0.93 (0.55–1.57) | ||||
Swedish construction workers: Bolinder et al. 1994 [28] | Snuff | Current | Never | M | 9 | 96 | 1.10 (0.90–1.40) | age, res |
Uppsala County: Roosaar et al. 2008 [35] | Snuff | Ever | Any | M | 10 | 237 | 1.00 (0.87–1.15) | age, alc, res, smok, time |
Never | 11 | 138 | 1.10 (0.90–1.40) | age, alc, res, time | ||||
Case-control studies
| ||||||||
Sterling et al. 1992 [89] | ST | Ever | Any | M+F | 12 | 2,498g
| 0.64 (0.53–0.78)f
| age, alc, occ, race, sex, smok |
Heterogeneity | ||||||
---|---|---|---|---|---|---|
Type of ST (region)a
| Adjustments/restrictionsb
| Number of estimates (RR/OR ids)c
| Random-effects RR/OR (95% CI) | χ2
| I2
|
P(χ2) |
Any | Overall data | 7 (1, 2, 3, 6, 9, 10, 12) | 0.98 (0.84–1.15) | 27.1 | 77.9 | < 0.001 |
Smoking-adjusted | 7 (1, 2, 3, 6, 9, 10, 12) | 0.98 (0.84–1.15) | 27.1 | 77.9 | < 0.001 | |
Never smokers | 6 (1, 2, 3, 6, 9, 11) | 1.10 (1.02–1.19) | 1.5 | 0.0 | 0.911 | |
Any (USA) | Overall data | 5 (1, 2, 3, 6, 12) | 0.95 (0.74–1.22) | 26.5 | 84.9 | < 0.001 |
Smoking-adjusted | 5 (1, 2, 3, 6, 12) | 0.95 (0.74–1.22) | 26.5 | 84.9 | < 0.001 | |
Never smokers | 4 (1, 2, 3, 6) | 1.10 (1.01–1.20) | 1.5 | 0.0 | 0.679 | |
Snuff (Scandinavia) | Overall data | 2 (9, 10) | 1.03 (0.91–1.16) | 0.5 | 0.0 | 0.475 |
Smoking-adjusted | 2 (9, 10) | 1.03 (0.91–1.16) | 0.5 | 0.0 | 0.475 | |
Never smokers | 2 (9, 11) | 1.10 (0.94–1.29) | 0.0 | 0.0 | 1.000 |
Publication bias
Sensitivity analyses
Cancer (number of estimates) | RR/OR estimate removed | Heterogeneity | Random-effects RR/OR (95% CI) | |||
---|---|---|---|---|---|---|
Id. | RR/OR | Q2
| χ2
|
P
| ||
Oropharyngeal (n = 19) | 69.5 | < 0.001 | 1.36 (1.04–1.77) | |||
35 | 2.67 (1.83–3.90) | 15.6 | 52.2 | < 0.001 | 1.27 (0.99–1.64) | |
13 | 2.05 (1.48–2.83) | 12.2 | 37.9 | 0.002 | 1.20 (0.94–1.52) | |
43 | 6.20 (1.90–19.80) | 8.9 | 28.9 | 0.017 | 1.11 (0.90–1.38) | |
7 | 0.70 (0.50–0.90) | 6.2 | 21.0 | 0.101 | 1.17 (0.95–1.45) | |
Pancreatic (n = 7) | 21.2 | 0.002 | 1.07 (0.71–1.60) | |||
5 | 1.67 (1.12–2.50) | 6.0 | 13.8 | 0.017 | 0.95 (0.63–1.46) | |
1 | 1.70 (0.90–3.10) | 4.1 | 9.2 | 0.057 | 0.83 (0.54–1.28) | |
Overall digestive (n = 5) | 17.3 | 0.002 | 0.86 (0.59–1.25) | |||
19 | 0.40 (0.24–0.69) | 13.3 | 3.1 | 0.382 | 1.14 (0.99–1.33) | |
Lung (n = 6) | 28.7 | < 0.001 | 0.99 (0.71–1.37) | |||
6 | 1.77 (1.14–2.74) | 15.5 | 12.7 | 0.013 | 0.83 (0.63–1.08) | |
2 | 6.80 (1.60–28.5) | 9.4 | 3.3 | 0.343 | 0.72 (0.65–0.80) | |
Bladder (n = 10) | 22.3 | 0.008 | 0.95 (0.71–1.29) | |||
12 | 1.67 (1.09–2.55) | 6.9 | 14.3 | 0.074 | 0.86 (0.65–1.13) | |
Non-Hodgkin's lymphoma (n = 3) | ||||||
9.5 | 0.009 | 1.35 (0.62–2.95) | ||||
19 | 4.00 (1.30–12.0) | 6.9 | 2.2 | 0.137 | 0.92 (0.57–1.50) | |
Overall (n = 7) | 27.1 | < 0.001 | 0.98 (0.84–1.15) | |||
12 | 0.64 (0.53–0.78) | 21.4 | 2.8 | 0.725 | 1.07 (1.00–1.15) |
Heterogeneity | |||||
---|---|---|---|---|---|
Cancer | Analysisa
|
N (nc)b
| Random-effects RR/OR (95% CI) | χ2
|
P
|
Oropharyngeal | Table 4 | 19 | 1.36 (1.04–1.77) | 69.5 | < 0.001 |
Sensitivity | (5) | 1.42 (1.10–1.84) | 51.1 | < 0.001 | |
Oesophageal | Table 6 | 7 | 1.13 (0.95–1.36) | 4.4 | 0.623 |
Sensitivity | (2) | 1.11 (0.92–1.34) | 4.1 | 0.665 | |
Stomach | Table 8 | 8 | 1.03 (0.88–1.20) | 10.3 | 0.173 |
Sensitivity | (2) | 1.01 (0.86–1.19) | 10.4 | 0.165 | |
Pancreatic | Table 10 | 7 | 1.07 (0.71–1.60) | 21.5 | 0.001 |
Sensitivity | (2) | 1.22 (0.75–2.01) | 23.1 | < 0.001 | |
Overall digestive | Table 12 | 5 | 0.86 (0.59–1.25) | 17.3 | 0.002 |
Sensitivity | (1) | 0.85 (0.57–1.27) | 17.3 | 0.002 | |
Larynx | Table 14 | 2 | 1.34 (0.61–2.95) | 4.0 | 0.044 |
Sensitivity | (1) | 1.45 (0.73–2.88) | 2.5 | 0.116 | |
Lung | Table 16 | 6 | 0.99 (0.71–1.37) | 28.7 | < 0.001 |
Sensitivity | (3) | 1.11 (0.73–1.69) | 20.6 | < 0.001 | |
Prostate | Table 18 | 4 | 1.29 (1.07–1.55) | 1.2 | 0.764 |
Sensitivity | (0) | ||||
Bladder | Table 20 | 10 | 0.95 (0.71–1.29) | 22.3 | 0.008 |
Sensitivity | (1) | 0.94 (0.68–1.29) | 23.7 | 0.005 | |
Kidney | Table 22 | 5 | 1.09 (0.69–1.71) | 6.9 | 0.142 |
Sensitivity | (1) | 1.07 (0.60–1.91) | 9.6 | 0.048 | |
Non-Hodgkin's lymphoma | Table 24 | 3 | 1.35 (0.62–2.94) | 9.5 | 0.009 |
Sensitivity | (0) | ||||
Overall | Table 27 | 7 | 0.98 (0.84–1.15) | 27.1 | < 0.001 |
Sensitivity | (1) | 0.99 (0.83–1.17) | 27.9 | < 0.001 |
Meta-regression analyses
Summary of meta-analyses for ST use in Western populations
Overall data | Smoking-adjusted data | Never smokers | ||||
---|---|---|---|---|---|---|
Cancer |
n
| RR/OR (95% CI) |
n
| RR/OR (95% CI) |
n
| RR/OR (95% CI) |
Oropharyngeal (Table 4) | 41 | 1.79 (1.36–2.36) | 19 | 1.36 (1.04–1.77) | 9 | 1.72 (1.01–2.94) |
- (published since 1990) | 18 | 1.28 (0.94–1.76) | 14 | 1.00 (0.83–1.20) | 7 | 1.24 (0.80–1.90) |
Oesophageal (Table 6) | 10 | 1.25 (1.03–1.51) | 7 | 1.13 (0.95–1.36) | 4 | 1.91 (1.15–3.17) |
Stomach (Table 8) | 9 | 1.03 (0.90–1.19) | 8 | 1.03 (0.88–1.20) | 4 | 1.27 (0.75–2.13) |
Pancreatic (Table 10) | 7 | 1.00 (0.68–1.47) | 7 | 1.07 (0.71–1.60) | 5 | 1.23 (0.66–2.31) |
Any digestive (Table 12) | 5 | 0.86 (0.59–1.25) | 5 | 0.86 (0.59–1.25) | 4 | 1.14 (0.99–1.33) |
Larynx (Table 14) | 5 | 1.43 (1.08–1.89) | 2 | 1.34 (0.61–2.95) | 0 | - |
Lung (Table 16) | 9 | 0.96 (0.73–1.27) | 6 | 0.99 (0.71–1.37) | 5 | 1.34 (0.80–2.23) |
Prostate (Table 18) | 5 | 1.20 (1.03–1.40) | 4 | 1.29 (1.07–1.55) | 3 | 1.81 (0.76–4.30) |
Bladder (Table 20) | 14 | 1.00 (0.80–1.25) | 10 | 0.95 (0.71–1.29) | 6 | 1.10 (0.60–2.02) |
Kidney (Table 22) | 11 | 1.23 (0.86–1.76) | 5 | 1.09 (0.69–1.71) | 2 | 2.19 (0.63–7.70) |
Non-Hodgkin's lymphoma (Table 24) | 5 | 1.20 (0.83–1.75) | 3 | 1.35 (0.62–2.95) | 3 | 1.35 (0.62–2.95) |
Overall cancer (Table 27) | 7 | 0.98 (0.84–1.15) | 7 | 0.98 (0.84–1.15) | 6 | 1.10 (1.02–1.19) |
Summary of meta-analyses for ST use in the USA
Overall data | Smoking-adjusted data | Never smokers | ||||
---|---|---|---|---|---|---|
Cancer |
n
| RR/OR (95% CI) |
n
| RR/OR (95% CI) |
n
| RR/OR (95% CI) |
Oropharyngeal (Table 4) | 31 | 2.16 (1.55–3.02) | 12 | 1.65 (1.22–2.25) | 5 | 3.33 (1.76–6.32) |
Oesophageal (Table 6) | 6 | 1.56 (1.11–2.19) | 3 | 1.89 (0.84–4.25) | 3 | 1.89 (0.84–4.25) |
Stomach (Table 8) | 4 | 1.41 (0.95–2.10) | 3 | 1.41 (0.93–2.12) | 2 | 1.96 (0.82–4.70) |
Pancreatic (Table 10) | 5 | 0.86 (0.47–1.57) | 5 | 0.99 (0.51–1.91) | 3 | 1.09 (0.44–2.67) |
Any digestive (Table 12) | 5 | 0.86 (0.59–1.25) | 5 | 0.86 (0.59–1.25) | 4 | 1.14 (0.99–1.33) |
Larynx (Table 14) | 4 | 1.56 (1.21–2.00) | 1 | 2.01 (1.15–3.51) | 0 | -- |
Lung (Table 16) | 6 | 1.22 (0.82–1.83) | 4 | 1.38 (0.72–2.64) | 3 | 1.79 (0.91–3.51) |
Prostate (Table 18) | 5 | 1.23 (1.03–1.40) | 4 | 1.29 (1.07–1.55) | 3 | 1.81 (0.76–4.30) |
Bladder (Table 20) | 9 | 1.11 (0.85–1.45) | 6 | 1.24 (0.83–1.85) | 5 | 1.25 (0.69–2.26) |
Kidney (Table 22) | 8 | 1.52 (0.94–2.46) | 3 | 1.41 (0.64–3.10) | 1 | 4.80 (1.18–19.56) |
Non-Hodgkin's lymphoma (Table 24) | 3 | 1.45 (0.81–2.59) | 2 | 2.07 (0.70–6.13) | 2 | 2.07 (0.70–6.13) |
Overall cancer (Table 27) | 5 | 0.95 (0.74–1.22) | 5 | 0.95 (0.74–1.22) | 4 | 1.10 (1.01–1.20) |
Summary of meta-analyses for snuff use in Scandinavia
Overall data* | Never smokers | |||
---|---|---|---|---|
Cancer (source) |
n
| RR/OR (95% CI) |
N
| RR/OR (95% CI) |
Oropharyngeal (Table 4) | 7 | 0.97 (0.68–1.37) | 4 | 1.01 (0.71–1.45) |
Oesophageal (Table 6) | 4 | 1.10 (0.92–1.33) | 1 | 1.92 (1.00–3.68) |
Stomach (Table 8) | 5 | 0.98 (0.82–1.17) | 2 | 0.90 (0.35–2.30) |
Pancreatic (Table 10) | 2 | 1.20 (0.66–2.20) | 2 | 1.61 (0.77–3.34) |
Larynx (Table 14) | 1 | 0.90 (0.50–1.50) | 0 | - |
Lung (Table 16) | 2 | 0.71 (0.66–0.76) | 2 | 0.82 (0.52–1.28) |
Bladder (Table 20) | 1 | 0.83 (0.62–1.11) | 0 | - |
Kidney (Table 22) | 1 | 0.72 (0.44–1.18) | 0 | - |
Non-Hodgkin's lymphoma (Table 24) | 2 | 1.04 (0.54–1.98) | 1 | 0.77 (0.59–1.01) |
Overall cancer (Table 27) | 2 | 1.03 (0.91–1.16) | 2 | 1.10 (0.94–1.29) |
Dose response data
Comparison of the effects of smoking and of ST use
Oropharynx | Oesophagus | Pancreas | Larynx | Lung | Bladder | Kidney | Total | |
---|---|---|---|---|---|---|---|---|
Number of deaths (Di)b
| 5,224 | 10,578 | 16,105 | 2,980 | 90,096 | 9,181 | 8,041 | 142,205 |
Relative risksc
| ||||||||
Current cigarette smoking (Rci) | 27.48 | 7.60 | 2.14 | 10.48 | 22.36 | 2.86 | 2.95 | |
Former cigarette smoking (Rfi) | 8.80 | 5.83 | 1.12 | 5.24 | 9.36 | 1.90 | 1.95 | |
Deaths if all the population were never smokers (Di*)d
| 567 | 2,681 | 12,524 | 679 | 10,901 | 5,445 | 4,671 | 37,468 |
Deaths eliminated if all the population were never smokers (E)e
| 104,737 | |||||||
Relative risksf
| ||||||||
- any ST use (Rsi) | 1.36 | 1.13 | 1.07 | 1.34 | 1.00g
| 1.00h
| 1.09 | |
Deaths in a population of never smokersi
| ||||||||
Same % become ST users as were smokers (Di**) | 676 | 2,866 | 12,988 | 801 | 10,901 | 5,445 | 4,894 | 38,570 |
100% of population become ST users (Di***) | 772 | 3,029 | 13,400 | 910 | 10,901 | 5,445 | 5,091 | 39,548 |
Increase in deaths in a population of never smokersj
| ||||||||
Same % become ST users as were smokers (I1) | 1,102 | |||||||
100% of population become ST users (I2) | 2,081 |